Ginkgo Bioworks Holdings, Inc.
For the period ended Jun 11, 2026. Filed Apr 29, 2026.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Jun 11, 2026 · Filed Apr 29, 2026
Contents
Summary Compensation Table
The following table sets forth information concerning the compensation of Ginkgo’s named executive officers for the years ended December 31, 2025, December 31, 2024 and December 31, 2023.
| Name and Principal Position | Year | Salary($) | StockAwards($)(1) | Option Awards ($)(2) | All OtherCompensation($)(3) | Total($) |
|---|---|---|---|---|---|---|
| Jason Kelly | 2025 | 250,000 | 5,454,049 | - | 5,000 | 5,709,049 |
| Chief Executive Officer | 2024 | 250,000 | - | 981,000 | - | 1,231,000 |
| 2023 | 250,000 | - | - | 12,019 | 262,019 | |
| Reshma Shetty | 2025 | 250,000 | 3,224,364 | - | 5,000 | 3,479,364 |
| President & Former Chief Operating Officer | 2024 | 250,000 | - | 981,000 | - | 1,231,000 |
| 2023 | 250,000 | - | - | 12,019 | 262,019 | |
| Steven Coen(4) | 2025 | 433,692 | 893,633 | - | 5,000 | 1,332,326 |
| Chief Financial Officer | ||||||
| Mark Dmytruk(5) | 2025 | 212,308 | 169,633 | - | 5,000 | 386,941 |
| Former Chief Financial Officer | 2024 | 460,000 | 1,320,000 | - | - | 1,780,000 |
| 2023 | 460,000 | 1,218,000 | - | 16,500 | 1,694,500 | |
(1) Amounts reflect the grant date fair value of RSUs and PSUs awarded, computed in accordance with FASB ASC Topic 718, excluding the effect of estimated forfeitures. For the RSUs, the grant date fair value was calculated by multiplying the closing price of the Company’s Class A common stock on the grant date by the number of RSUs granted. For the PSUs, the grant date fair value is based on the probable outcome of the applicable performance conditions, which assumes that the performance conditions are met in full. We provide information regarding the assumptions used to calculate the fair value of all RSU and PSU awards made in Note 14 to the consolidated financial statements included in our 2025 Annual Report on Form 10-K.
(2) Amounts for 2024 reflect the grant date fair value of the Founder Options awarded, computed in accordance with FASB ASC Topic 718, excluding the effect of estimated forfeitures, based on the probable outcome of the applicable performance conditions, which assumes that the performance conditions are met in full. We provide information regarding the assumptions used to calculate the fair value of all option awards made to named executive officers in Note 14 to the consolidated financial statements included in our 2025 Annual Report on Form 10-K.
(3) Amounts for 2025 and 2023 represent employer non-elective contributions under Ginkgo’s 401(k) plan.
(4) Mr. Coen was appointed as Chief Financial Officer effective May 30, 2025. No amounts are reported in this table for Mr. Coen prior to 2025 because Mr. Coen was not a named executive officer prior to 2025.
(5) Mr. Dmytruk resigned from the Company effective June 6, 2025.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.